Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Scientific Officer

12 Jul 2021 14:30

RNS Number : 9657E
Midatech Pharma PLC
12 July 2021
 

12 July 2021

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Midatech Strengthens Management Team

with

Appointment of Dr Dmitry Zamoryakhin as Chief Scientific Officer

 

Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the appointment of Dr Dmitry Zamoryakhin as Chief Scientific Officer, a non-board role, with immediate effect.

Dr Zamoryakhin has broad experience across all phases of development of drugs and medical devices, working with regulatory authorities including the EMA, FDA, PMDA, and NMPA. Most recently, he was Chief Medical Officer of Oxford Biomedica plc (LON: OXB), having previously held positions of increasing responsibility at Grunenthal GmbH, Daiichi Sankyo Company Limited (TYO: 4568), Ono Pharmaceutical Co., Limited (TYO: 4528) and GlaxoSmithKline plc (LON:GSK, NYSE: GSK). He qualified as a doctor of medicine at Perm State Medical Academy, Russia, before earning a diploma in Pharmaceutical Medicine at PHARMED, Universite Libre de Bruxelles, and an MBA at Warwick Business School.

Dr Zamoryakhin will take over from Steve Damment, EVP R&D who, after six years with the Company, has decided to retire from full-time employment at the end of September 2021.

Commenting, Stephen Stamp, CEO and CFO of Midatech said: "I am delighted to welcome Dmitry to the Midatech team. He is a medic, was big pharma trained and has been biotech battle hardened. His breadth of experience will be invaluable as we move our Q-Sphera programmes and MTX110 through proof of concept to partnering.

"On behalf of everybody at Midatech, I should also like to express our thanks to Steve Damment for his service to the Company and, in particular, the key role he has played in championing MTX110."

For more information, please contact:

Midatech Pharma PLC

Stephen Stamp, CEO, CFO

Tel: +44 (0)29 2048 0180

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0)20 7886 2500

Turner Pope Investments (TPI) Limited (Joint Broker)

Andrew Thacker / James Pope (Corporate Broking)

Tel: +44(0)20 3657 0050

 

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations)

Maxwell Colbert

Tel: +1 (646) 653 7028

Email: mcolbert@edisongroup.com

 

 

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

· Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

· MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

· MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.

 

The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com

Forward-Looking Statements

 

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUPPMUPGGWP
Date   Source Headline
10th Mar 20235:52 pmRNSFurther re: Notice of General Meeting
8th Mar 20237:00 amRNSPosting of Circular and Notice of General Meeting
17th Feb 20237:00 amRNSHolding(s) in Company
16th Feb 20237:00 amRNSHolding(s) in Company
15th Feb 20232:49 pmRNSHolding(s) in Company
15th Feb 20231:36 pmRNSHolding(s) in Company
15th Feb 20231:26 pmRNSHolding(s) in Company
15th Feb 20238:05 amRNSClosing of $6.0m Private Placement & Broker Change
9th Feb 20235:10 pmRNSPrivate Placement Raising US$6.0 million
3rd Feb 20239:57 amRNSReceipt of NASDAQ Notice
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 202312:00 pmRNSResult of General Meeting
16th Jan 202311:24 amRNSHolding(s) in Company
12th Jan 20237:00 amRNSPlanned Dose Escalation in MTX-110 Phase 1 Study
6th Jan 20237:00 amRNSPosting of Circular and Notice of General Meeting
19th Dec 202212:06 pmRNSHolding(s) in Company
19th Dec 202210:48 amRNSHolding(s) in Company
19th Dec 20227:00 amRNSClosing of Offering, Revised Terms, AIM & Webinar
14th Dec 20222:05 pmRNSSecond Price Monitoring Extn
14th Dec 20222:00 pmRNSPrice Monitoring Extension
13th Dec 20224:40 pmRNSSecond Price Monitoring Extn
13th Dec 20224:35 pmRNSPrice Monitoring Extension
13th Dec 20223:22 pmRNSProposed Acquisition of Bioasis Technologies Inc
14th Nov 20227:00 amRNSFirst Patient Enrolled in Phase 1 Study of MTX-110
18th Oct 20227:00 amRNSReceipt of NASDAQ Notification
20th Sep 202211:51 amRNSHolding(s) in Company
14th Sep 20221:57 pmRNSADR Ratio Change
14th Sep 20227:00 amRNSInterim results for the six months to 30 June 2022
21st Jun 20227:00 amRNSMTX110 Development for the Treatment of Glioma
20th Jun 20225:58 pmRNSDirectorate Change
20th Jun 20222:33 pmRNSResult of 2022 Annual General Meeting
10th Jun 20227:00 amRNSRetirement of Chairman and Proposed New Chairman
10th Jun 20227:00 amRNSMTX110 Study to be Presented at ISPNO 2022
1st Jun 202212:23 pmRNSFast Track Designation for MTX110 Development
24th May 202211:09 amRNSPosting of Annual Report & Notice of AGM
27th Apr 20221:00 pmRNSIssue of Equity for Employee Share Incentive Plan
26th Apr 20227:00 amRNSResults for the Year Ended 31 December 2021
14th Apr 202212:37 pmRNSReceipt of NASDAQ Notice
17th Mar 20227:00 amRNSExercise of Warrants and Issue of Equity
9th Mar 20227:00 amRNSR&D collaboration with Janssen on second molecule
8th Mar 20229:30 amRNSAppointment of Nominated and Financial Adviser
9th Feb 20221:53 pmRNSHolding(s) in Company
18th Jan 20224:18 pmRNSHolding(s) in Company
17th Jan 20227:00 amRNSExtension of Janssen collaboration re Q-Sphera
7th Jan 20225:37 pmRNSHolding(s) in Company
13th Dec 20219:43 amRNSIND Application for MTX110 Study in GBM Effective
3rd Dec 20217:00 amRNSMidatech presenting at MelloMonday
24th Nov 20217:00 amRNSMidatech presenting at the Shares/AJ Bell Webinar
17th Sep 20219:31 amRNSInterim results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.